3 completed, 3 unknown, 2 active not recruiting, 1 terminated. 9 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 3, Unknown 3, Active not recruiting 2, Terminated 1 |
| Phase 2 | 1 | Terminated 1 |
Follow Pharmacogenomic Testing: new trials by email Literature Review of Pharmacogenomic Testing trials Research Report on Pharmacogenomic Testing
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacogenetics in Primary Care Psychotropics Pharmacogenetic testing - Depression, Obsessive-Compulsive Disorder | Phase 3 | Unknown | University of Arizona | 130 | 2017-08-15 | 2017-07-28 |
| Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Autologous Bone Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, Carmustine - Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 94 | 2016-10-12 | 2026-11-13 |
| Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Cyclophosphamide, Fludarabine Phosphate, Ibrutinib - Anemia, Chronic Lymphocytic Leukemia | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 529 | 2014-03-10 | 2026-08-28 |
| Pazopanib Hydrochloride or a Placebo in Treating Patients With Non-Small Cell Lung Cancer Who Have Received First-Line Chemotherapy pazopanib hydrochloride, laboratory biomarker analysis, pharmacogenomic studies - Lung Cancer | Phase 2 / Phase 3 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 102 | 2011-07-01 | 2018-07-12 |
| Genetics Informatics Trial (GIFT) of Warfarin to Prevent DVT Pharmacogenetic, Target INR 1.8 - Thromboembolism | Phase 3 | Completed | Washington University School of Medicine | 1598 | 2011-03-01 | 2016-12-29 |
| Transarterial Chemoembolization Using Doxorubicin Beads With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery doxorubicin-eluting beads, sorafenib tosylate, laboratory biomarker analysis - Liver Cancer | Phase 3 | Unknown | University College, London | 412 | 2010-11-01 | 2011-05-13 |
| Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pharmacogenomic Study - Advanced Adult Hepatocellular Carcinoma, Recurrent Hepatocellular Carcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 356 | 2010-02-15 | 2026-06-24 |
| Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain ketamine hydrochloride, pharmacogenomic studies, questionnaire administration - Cancer | Phase 3 | Unknown | University of Glasgow | 214 | 2009-04-01 | 2011-05-13 |
| Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer gemcitabine hydrochloride, bevacizumab, placebo - Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer | Phase 3 | Completed | National Cancer Institute (NCI) | 590 | 2004-06-01 | 2013-06-05 |
Carcinoma, Hepatocellular (2) · Depression (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Adenocarcinoma of Lung (1) · Adenocarcinoma, Bronchiolo-Alveolar (1) · Anemia (1) · Anxiety Disorders (1) · Blast Crisis (1) · Burkitt Lymphoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Congenital Abnormalities (1) · Generalized Anxiety Disorder (1) · Hodgkin Disease (1) · Immunoblastic Lymphadenopathy (1) · Immunoglobulin Light-chain Amyloidosis (1)
National Cancer Institute (NCI) (4) · European Organisation for Research and Treatment of Cancer - EORTC (1) · University College, London (1) · University of Arizona (1) · University of Glasgow (1) · Washington University School of Medicine (1)
United States (5) · United Kingdom (3) · Belgium (1) · Canada (1) · Egypt (1) · France (1) · Germany (1) · Greece (1) · Netherlands (1) · Puerto Rico (1) · Saudi Arabia (1) · Slovenia (1)
Barry J.A. Laird, MD (1) · Brian F Gage, MD, MSc (1) · Charalambos B Andreadis (1) · Ghassan K Abou-Alfa (1) · Hedy Kindler (1) · Marie T. Fallon (1) · Mary O'Brien, MD (1) · Tait D Shanafelt (1) · Tim Meyer, MD, BSc, MRCP, PhD (1)
PMID 28973620, PMID 31365801, PMID 31479138, PMID 31486832, PMID 33439748, PMID 34028627, PMID 34616010, PMID 34865212, PMID 35427411, PMID 35484400, PMID 37801678
U10CA031946 (2), U10CA180821 (2), R01CA193541 (1), R01HL097036 (1), U10CA021115 (1), U10CA180820 (1), U24CA196172 (1)